DK1631275T3 - Behandling og forebyggelse af excessiv ardannelse med 4-hydroxy-tamoxifen - Google Patents

Behandling og forebyggelse af excessiv ardannelse med 4-hydroxy-tamoxifen

Info

Publication number
DK1631275T3
DK1631275T3 DK04740032T DK04740032T DK1631275T3 DK 1631275 T3 DK1631275 T3 DK 1631275T3 DK 04740032 T DK04740032 T DK 04740032T DK 04740032 T DK04740032 T DK 04740032T DK 1631275 T3 DK1631275 T3 DK 1631275T3
Authority
DK
Denmark
Prior art keywords
excessive scarring
tamoxifen
hydroxy
prevention
treatment
Prior art date
Application number
DK04740032T
Other languages
Danish (da)
English (en)
Inventor
Andrew R Palumbo
Julius Few
Dana C Hilt
Original Assignee
Ascend Therapeutics Inc
Univ Northwestern
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ascend Therapeutics Inc, Univ Northwestern filed Critical Ascend Therapeutics Inc
Application granted granted Critical
Publication of DK1631275T3 publication Critical patent/DK1631275T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061Use of materials characterised by their function or physical properties
    • A61L26/0066Medicaments; Biocides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/416Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Materials Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK04740032T 2003-06-09 2004-06-02 Behandling og forebyggelse af excessiv ardannelse med 4-hydroxy-tamoxifen DK1631275T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47661803P 2003-06-09 2003-06-09
PCT/EP2004/006583 WO2004110420A1 (en) 2003-06-09 2004-06-02 Treatment and prevention of excessive scarring with 4-hydroxy tamoxifen

Publications (1)

Publication Number Publication Date
DK1631275T3 true DK1631275T3 (da) 2008-08-18

Family

ID=33551623

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04740032T DK1631275T3 (da) 2003-06-09 2004-06-02 Behandling og forebyggelse af excessiv ardannelse med 4-hydroxy-tamoxifen

Country Status (12)

Country Link
US (1) US7767717B2 (https=)
EP (1) EP1631275B1 (https=)
JP (1) JP4682129B2 (https=)
AT (1) ATE393625T1 (https=)
AU (1) AU2004246812B8 (https=)
CA (1) CA2528431C (https=)
DE (1) DE602004013439T2 (https=)
DK (1) DK1631275T3 (https=)
ES (1) ES2304610T3 (https=)
NZ (1) NZ544031A (https=)
PT (1) PT1631275E (https=)
WO (1) WO2004110420A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60327363D1 (de) 2002-12-18 2009-06-04 Besins Int Lab Verringerung der dichte des brustgewebes durch 4-hydroxy tamoxifen
MXPA05006526A (es) * 2002-12-18 2006-02-17 Besins Int Lab Tratamiento de mastalgia con 4-hidroxi tamoxifen.
ES2456958T3 (es) * 2003-04-01 2014-04-24 Besins Healthcare Luxembourg Sarl Formulaciones para prevención y tratamiento de cáncer de seno con 4-hidroxi tamoxifen
US7968532B2 (en) 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
PT1694319E (pt) * 2003-12-15 2008-10-24 Besins Int Lab Utilização de 4-hidroxi-tamoxifeno na preparação de um medicamento para o tratamento da ginecomastia
US7507769B2 (en) * 2004-03-22 2009-03-24 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
US20050208139A1 (en) * 2004-03-22 2005-09-22 Ascend Therapeutics, Inc. Chemically stable compositions of 4-hydroxy tamoxifen
EP1647271A1 (en) * 2004-10-14 2006-04-19 Laboratoires Besins International 4-Hydroxy tamoxifen gel formulations
JP5189093B2 (ja) * 2006-07-31 2013-04-24 ラボラトワール・ベザン・ザンテルナショナル 過剰瘢痕化の治療および予防
EP1891945A1 (en) * 2006-07-31 2008-02-27 Laboratoires Besins International Treatment and prevention of excessive scarring
EP2252320A2 (en) * 2007-12-21 2010-11-24 Coda Therapeutics, Inc. Use of anti-connexin polynucleotides and peptides for the treatment of abnormal or excessive scars
EP2252690A2 (en) * 2007-12-21 2010-11-24 Coda Therapeutics, Inc. Use of anti-connexin 43 polynucleotides for the treatment of abnormal or excessive scars
US20140350117A1 (en) * 2013-05-22 2014-11-27 Professional Compounding Centers Of America Topical Scar Treatment Composition and Method of Using Same
US20140350106A1 (en) * 2013-05-22 2014-11-27 Professional Compounding Centers Of America Urea Silicone Gel for Scars and Hydration Treatment and Method of Using Same
CN111163784B (zh) * 2017-09-01 2024-07-26 黄玲惠 用于治疗蟹足肿的药物组合物及其用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2558373B1 (fr) * 1984-01-20 1987-07-03 Mauvais Jarvis Pierre Medicament antioestrogene a base de 4-hydroxytamoxifene pour administration percutanee
ATE80152T1 (de) 1987-04-21 1992-09-15 Heumann Pharma Gmbh & Co Stabile loesungsmitteladdukte von z-1-(p-betadimethylamino-ethoxyphenyl)-1-(p-hydroxyphenyl) 2-phenylbut-1-en.
US5045553A (en) 1987-06-24 1991-09-03 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutical composition for percutaneous drug absorption and percutaneous drug absorption promoter
DE3836862A1 (de) 1988-10-27 1990-05-03 Schering Ag Mittel zur transdermalen applikation von steroidhormonen
WO1991001624A2 (en) * 1989-07-31 1991-02-21 Massachusetts Institute Of Technology Use of calcium antagonists for treating scars
TW218849B (https=) 1991-05-17 1994-01-11 Bristol Myers Squibb Co
ATE341316T1 (de) * 1992-07-20 2006-10-15 Massachusetts Inst Technology Kontrolle der wundvernarbung mit calmodulin- inhibitoren oder protein-kinase-c-inhibitoren
US5552162A (en) * 1993-02-09 1996-09-03 Arch Development Corporation Method for improvement of scar size and appearance
US5613958A (en) 1993-05-12 1997-03-25 Pp Holdings Inc. Transdermal delivery systems for the modulated administration of drugs
US5720963A (en) 1994-08-26 1998-02-24 Mary Kay Inc. Barrier disruption treatments for structurally deteriorated skin
EP1043986B1 (en) * 1997-12-23 2003-04-16 Hexal Ag Mixture and pharmaceutical composition comprising z-4-hydroxytamoxifen and cyclodextrin
US6013270A (en) 1998-04-20 2000-01-11 The Procter & Gamble Company Skin care kit
DE10033853A1 (de) 2000-07-12 2002-01-31 Hexal Ag Transdermales therapeutisches System mit hochdispersem Siliziumdioxid
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
DK1317921T3 (da) 2001-12-07 2009-12-21 Besins Mfg Belgium Farmaceutisk sammensætning i form af en gel eller oplösning med dihydrotestosteron, fremgangsmåde til fremstilling og anvendelser heraf
DE60327363D1 (de) 2002-12-18 2009-06-04 Besins Int Lab Verringerung der dichte des brustgewebes durch 4-hydroxy tamoxifen
MXPA05006526A (es) 2002-12-18 2006-02-17 Besins Int Lab Tratamiento de mastalgia con 4-hidroxi tamoxifen.
ES2456958T3 (es) 2003-04-01 2014-04-24 Besins Healthcare Luxembourg Sarl Formulaciones para prevención y tratamiento de cáncer de seno con 4-hidroxi tamoxifen
US7968532B2 (en) 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
US20050208139A1 (en) 2004-03-22 2005-09-22 Ascend Therapeutics, Inc. Chemically stable compositions of 4-hydroxy tamoxifen
US7507769B2 (en) 2004-03-22 2009-03-24 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
EP1579856A1 (en) 2004-03-22 2005-09-28 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
EP1647271A1 (en) 2004-10-14 2006-04-19 Laboratoires Besins International 4-Hydroxy tamoxifen gel formulations

Also Published As

Publication number Publication date
HK1082203A1 (en) 2006-06-02
JP4682129B2 (ja) 2011-05-11
JP2006527234A (ja) 2006-11-30
DE602004013439T2 (de) 2009-06-04
AU2004246812B2 (en) 2009-12-17
US20050032910A1 (en) 2005-02-10
ES2304610T3 (es) 2008-10-16
CA2528431C (en) 2012-09-18
EP1631275B1 (en) 2008-04-30
EP1631275A1 (en) 2006-03-08
PT1631275E (pt) 2008-08-04
WO2004110420A1 (en) 2004-12-23
AU2004246812A1 (en) 2004-12-23
DE602004013439D1 (de) 2008-06-12
US7767717B2 (en) 2010-08-03
AU2004246812B8 (en) 2010-01-14
CA2528431A1 (en) 2004-12-23
ATE393625T1 (de) 2008-05-15
WO2004110420A8 (en) 2005-11-24
NZ544031A (en) 2008-08-29

Similar Documents

Publication Publication Date Title
DK1631275T3 (da) Behandling og forebyggelse af excessiv ardannelse med 4-hydroxy-tamoxifen
ATE551996T1 (de) Behandlung oder prävention von diabetes mit cannabidiol
DK1545587T3 (da) Lactoferrinsammensætninger og fremgangsmåder til behandling af diabetiske sår
BRPI0510925A (pt) métodos e composições para cicatrização de ferida
ATE526959T1 (de) Behandlung von muskelschwund mit selektiven androgenrezeptormodulatoren
EA202192122A1 (ru) Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения
DK1651161T3 (da) Farmaceutiske præparater og fremgangsmåder til at fremme sårheling
NO20091661L (no) Anvendelse av pegylert IL-10 for a behandle kreft
ATE534378T1 (de) Titrierung von tapentadol
CL2007002384A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de la psoriasis.
CY1106026T1 (el) Αρυλσουλφοναμιδια ως ανταγωνιστες της σepοτονινης για την αγωγη της παχυσαρκιας
PT1492561E (pt) Metodo para tratar disturbios da glandula mamaria
CY1113959T1 (el) Χρηση λιποσωματων pvp-ιωδιου για θεραπεια ακμης
EA202091533A1 (ru) Способы лечения диабета, гепатита и/или воспалительного заболевания печени
BRPI0415678A (pt) compostos de pirimidina para o tratamento de inflamação
SE0200198D0 (sv) New use
ATE402694T1 (de) Verwendung von 1-phenyl-3-dimethylamino-propan- verbindungen zur therapie der harninkontinenz
ATE406171T1 (de) Aplidine zur behandlung von multiplem myelom
ATE344662T1 (de) Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
DK1368023T3 (da) Anvendelse af buprenoprphin til behandling af urininkontinens
BR0317491A (pt) Método de usar um inibidor de cox-2 e um inibidor de topoisomerase ii como uma terapia de combinação no tratamento de neoplasia
DK1523985T3 (da) Ikke-radioaktivt strontiumholdigt middel til behandling af kræft
ATE315387T1 (de) Verwendung von substituierten 6- dimethylaminomethyl-1-phenyl- cyclohexanverbindungen zur therapie der harninkontinenz
ATE410235T1 (de) Behandlung von ballastwasser
PT1601352E (pt) Utilização combinada de um fibrato e de orlistat para o tratamento da obesidade